Urovant Sciences Ltd. (UROV)

Trade UROV now with
2/12/2021 4:33:11 PM Urovant Sciences Q3 Loss/share $1.46 Vs. Loss $1.36 Year Ago
2/11/2021 8:11:05 AM Urovant Sciences Announces Progression Of URO-902 Phase 2a Trial
11/19/2020 8:18:04 AM Urovant Sciences Reports Positive Clinical Efficacy And Safety Data From Vibegron EMPOWUR Long Term Extension Study
10/7/2020 8:05:42 AM Urovant Sciences Enters 5-year U.S. Co-promotion Agreement With Sunovion Pharmaceuticals
6/18/2020 4:15:40 PM Urovant Sciences Q4 Loss/share $1.68 Vs. Loss $0.96 Year Ago
6/2/2020 8:09:25 AM Urovant Sciences Appoints Walt Johnston As SVP Of Commercial, Kenton Stewart As SVP Of Market Access
5/27/2020 8:07:47 AM Urovant Sciences Appoints Jim Hindman To Board
5/14/2020 8:12:22 AM Urovant Sciences Presents Positive Clinical Efficacy & Safety Data On Vibegron At Virtual AUA Annual Meeting
3/23/2020 4:10:59 PM Urovant Sciences Appoints James Robinson As President And CEO
3/2/2020 8:07:14 AM Urovant Sciences Announces Publication Of Phase 3 EMPOWUR Trial Results
2/4/2020 8:17:32 AM Urovant Sciences Reports Publication Of Safety And efficacy Results Of URO-902
12/30/2019 4:45:27 PM Urovant Sciences Announces Submission Of New Drug Application For Vibegron For Treatment Of Overactive Bladder
12/30/2019 8:08:03 AM Urovant Sciences Enters Into $300 Mln Term Loan Agreement With Sumitomo Dainippon Pharma
12/23/2019 8:05:53 AM Urovant Sciences Initiates Patient Enrollment In Phase 2a Study Of URO-902
10/31/2019 9:33:10 AM Urovant Sciences Announces Creation Of A Broad Sumitomo Dainippon-Roivant Strategic Alliance
9/6/2019 9:12:01 AM Roivant Sciences, Sumitomo Dainippon Pharma To Create Broad Strategic Alliance